RxDoctor Payments Data

Charles Simonson, MD

Internal Medicine · Marrero, LANPI 1376731588

Payments from drug & device makers

$1,001in general payments, 2019–2025

Across 42 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$257
  • Lilly USA, LLC$243
  • Otsuka America Pharmaceutical, Inc.$240
  • AbbVie$108
  • Johnson & Johnson$40
  • Acadia Pharmaceuticals Inc$29
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$1,001100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,001 in reported general payments places this provider in the 65th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$37,594
Medicare patients
58
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide66$57,589
EliquisApixaban76$34,672
LinzessLinaclotide11$7,260
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,627
JanuviaSitagliptin Phosphate23$6,608
Lacosamide36$4,596
Atorvastatin Calcium244$3,182
Mirtazapine81$2,097
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$1,681
Levetiracetam27$1,570
Quetiapine Fumarate100$1,562
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$1,365
Levothyroxine Sodium99$1,058
Divalproex Sodium11$1,008
Acetaminophen-CodeineAcetaminophen With Codeine27$853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$243$57,58966 claims
AbbVieLinzess$108$7,26011 claims
GSKAnoro Ellipta$11$6,62713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →